These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 1453209)

  • 41. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
    Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
    Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
    Jost LM; Jacky E; Dommann-Scherrer C; Honegger HP; Maurer R; Sauter C; Stahel RA
    Ann Oncol; 1995 May; 6(5):445-51. PubMed ID: 7545428
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
    Cabanillas F; Velasquez WS; McLaughlin P; Jagannath S; Hagemeister FB; Redman JR; Swan F; Rodriguez MA
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):47-50. PubMed ID: 3041599
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intensive cytoreductive therapy followed by autologous bone marrow transplantation for patients with hematologic malignancies or solid tumors.
    Verdonck LF; Dekker AW; Vendrik PJ; van Kempen ML; Schornagel JH; Rozenberg-Arska M; de Gast GC
    Cancer; 1987 Aug; 60(3):289-95. PubMed ID: 3297283
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Newcastle and Northern Lymphoma Group.
    Jackson GH; Lennard AL; Taylor PR; Carey P; Angus B; Lucraft H; Evans RG; Proctor SJ
    Br J Cancer; 1994 Sep; 70(3):501-5. PubMed ID: 7521662
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
    Yamanaka R; Shinbo Y; Sano M; Homma J; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Morii K; Onda K; Tanaka R
    Leuk Lymphoma; 2007 Jun; 48(6):1119-26. PubMed ID: 17577775
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.
    Colwill R; Crump M; Couture F; Danish R; Stewart AK; Sutton DM; Scott JG; Sutcliffe SB; Brandwein JM; Keating A
    J Clin Oncol; 1995 Feb; 13(2):396-402. PubMed ID: 7844600
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry.
    Williams CD; Pearce R; Taghipour G; Green ES; Philip T; Goldstone AH
    J Clin Oncol; 1994 Nov; 12(11):2415-22. PubMed ID: 7964958
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.
    Pfreundschuh MG; Rueffer U; Lathan B; Schmitz N; Brosteanu O; Hasenclever D; Haas R; Kirchner H; Koch P; Kuse R
    J Clin Oncol; 1994 Mar; 12(3):580-6. PubMed ID: 8120557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
    Wheeler C; Strawderman M; Ayash L; Churchill WH; Bierer BE; Elias A; Gilliland DG; Antman K; Guinan EC; Eder JP
    J Clin Oncol; 1993 Jun; 11(6):1085-91. PubMed ID: 8099120
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
    Fisher RI; Dana BW; LeBlanc M; Kjeldsberg C; Forman JD; Unger JM; Balcerzak SP; Gaynor ER; Roy V; Miller T
    J Clin Oncol; 2000 May; 18(10):2010-6. PubMed ID: 10811664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
    Stiff PJ; Dahlberg S; Forman SJ; McCall AR; Horning SJ; Nademanee AP; Blume KG; LeBlanc M; Fisher RI
    J Clin Oncol; 1998 Jan; 16(1):48-55. PubMed ID: 9440722
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL).
    Uyl-de Groot CA; Hagenbeek A; Verdonck LF; Löwenberg B; Rutten FF
    Bone Marrow Transplant; 1995 Sep; 16(3):463-70. PubMed ID: 8535321
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
    Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
    Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A pilot study of a response oriented chemotherapeutic regimen combined with autologous peripheral blood progenitor cell transplantation in aggressive non-Hodgkin's lymphoma.
    Tarumi T; Sawada K; Koizumi K; Takano H; Fukada Y; Nishio M; Fujie T; Ohnishi K; Kohno M; Sato N; Sekiguchi S; Koike T
    Leuk Lymphoma; 1999 Jul; 34(3-4):361-71. PubMed ID: 10439373
    [TBL] [Abstract][Full Text] [Related]  

  • 58. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma.
    Stein RS; Greer JP; Goodman S; Brandt SJ; Morgan DS; Macon WR; McCurley TL; Wolff SN
    Bone Marrow Transplant; 2000 Feb; 25(3):257-62. PubMed ID: 10673696
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.